SG/CALL/ASTRAZENECA/9000/0.1/20.09.24 Stock

SG/CALL/ASTRAZENECA/9000/0.1/20.09.24 Share Price

DE000SU9A8X0

Market Closed - Boerse Frankfurt Warrants 01:13:17 06/07/2024 am IST
3.52 ^EUR	-2.76%

Current month	-8.83%
1 month	-16.03%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart SG/CALL/ASTRAZENECA/9000/0.1/20.09.24

Latest news about ASTRAZENECA PLC

AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	05/07	MT
AstraZeneca: cancer treatment approved by the EU	05/07	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	05/07	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	05/07	MT

More news

Quotes 5-day view

Date	Price	Change
05/24/05	3.51	-3.04%
04/24/04	3.62	+2.55%
03/24/03	3.53	-1.94%
02/24/02	3.6	-6.01%
01/24/01	3.83	-0.52%

Real-time Boerse Frankfurt Warrants

Last update July 06, 2024 at 01:13 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Société Générale
WKN	SU9A8X
ISIN	DE000SU9A8X0
Date issued	14/02/2024
Strike	9,000 p
Maturity	20/09/2024 (76 Days)
Parity	10 : 1
Emission price	1.27 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.42 €
Lowest since issue	1.22 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	3.88x
Moneyness	1.340
Difference Strike	-3,056 p
Difference Strike %	-33.96%
Spread	0.28 €
Spread %	7.35%
Intrinsic value	3.612
Present value	0.0575

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company